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HumancytotoxicT lymphocytes(CTL) specific for influenzaAvirusgenerated
from. peripheral blood lymphocytes ofimmune donors show exquisite specificity
in their recognition of target cells that share class I molecules of the major
histocompatibility complex (MHC) (1). Polyclonal human CTL show full cross-
reactivity between all influenza A viruses (2, 3), but the nature of the viral
antigens that are recognized together with self HLA antigens on the surface of
infected cells is poorly defined . The influenza A virus genome codes for two
antigenically variable transmembrane glycoproteins, haemagglutinin and neura-
minidase, and eight more conserved internal proteins . Neutralizing antibody is
directed toward thevariable transmembrane glycoproteins and is subtype specific
(4) . In contrast, the virus determinants recognized by subtype crossreactiveCTL
now seem likely to be the more conserved internal antigens . Using arecombinant
vaccinia virus expressing the nucleoprotein (NP-VAC)' it was shown that some
human influenza A virus-specific CTL recognize the nucleoprotein molecule
(5) . Furthermore, a short synthetic peptide derived from the nucleoprotein
sequence is recognized by CTL in a manner restricted to a single class I MHC
antigen, HLA B37 (6, 7) . Murine CTL have also been shown to recognize the
individually expressed influenza virus haemagglutinin and nucleoprotein in trans-
fected L cells (8, 9) or in cells infected with recombinant vaccinia viruses (10,
11) . The nucleoprotein was found to be a major target antigen for murine
crossreactive CTL, and one of the polymerases has also been recognized by a
murine CTL clone (12 andJ . Bastin, John Radcliffe Hospital, Oxford, personal
communication) .
If vaccines are to be produced that boostCTL memory, and which might offer
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' Abbreviation used in this paper:
￿
PA-VAC, acidic polymerase-expressing recombinant vaccinia
virus ; PB1-VAC, basic polymerase 1-expressing recombinant vaccinia virus ; PB2-VAC, basic polym-
erase 2-expressing recombinant vaccinia virus ; NP-VAC, nucleoprotein-expressing recombinant
vaccinia virus ; NS1-VAC, nonstructural protein 1-expressing recombinant vaccinia virus ; M1-VAC,
matrix protein 1-expressing recombinant vaccinia virus ; NS2-VAC, nonstructural protein 2-express-
ing recombinant vaccinia virus ; M2-VAC, matrix protein 2-expressing recombinant vaccinia virus ;
NA-VAC, neuraminidase protein-expressing recombinant vaccinia virus ; H2-VAC, haemagglutinin
protein-expressing recombinant vaccinia virus .
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some degree of protection against new virus subtypes not provided by conven-
tional antibody-producing vaccines, a detailed characterization of which internal
antigens are recognized is necessary . To address this question, a series of vaccinia
virus recombinants, each expressing an individual influenza virus protein, have
been constructed. We report here the ability of CTL generated from donors of
different HLA haplotypes to recognize autologous cells infected with these
recombinant vaccinia viruses, and the influence that HLA type may have on this
recognition . We show that at least three internal virus proteins may be seen by
CTL with varying degrees of specific allelic HLA restriction. Some influenza
proteins were not seen by any individual tested.
Materials and Methods
Viruses.
￿
Influenza viruses AX31 and A/NT/60/68 were grown in allantoic cavities of
11-d-old embryonated chicken eggs, harvested and stored at -80 °C. Haemagglutinin
titers were between 1,000 and 2,000. Thymidine kinase-negative recombinant vaccinia
viruses containing influenza virus genes were constructed as described previously (13,
14). Recombinant vaccinia viruses PA-VAC, PB1-VAC, PB2-VAC, NP-VAC, NS1-VAC,
and M1-VAC contained cDNAs from influenza A/PR/8/34 corresponding to acidic
polymerase, basic polymerase 1, basic polymerase 2, nucleoprotein, nonstructural protein
1, and matrix protein 1, respectively. Recombinant vaccinia viruses NS2-VAC and M2-
VAC contained cDNA copies of mRNAs coding for nonstructural protein 2 and matrix
protein 2 of influenza A/Udorn/72 ; NA-VAC contains the neuraminidase gene of
A/Cam/1/46 and H2-VAC contains the haemagglutinin gene of A/Jap/305/57 (14). All
recombinant viruses have been shown to express the relevant influenza protein by
immunoprecipitation of [s5S]methionine-labelled infected cell extracts using specific an-
tiinfluenza antisera (5, 14, and G. Smith, unpublished data). NS2 and M2 were not
expressed by NS1-VAC and M1-VAC, respectively.
Wild type vaccinia virus (strain WR) and recombinant viruses were grown in HeLa
cells, purified from cytoplasmic extracts by sucrose density gradient centrifugation, and
stored at -80 ° C. Plaque-forming unit titers were determined on CV-1 cells.
Blood Donors.
￿
All donors were healthy volunteers. HLA types were determined by
the standard National Institutes of Health (NIH) technique. HLA types of all donors are
given in Table I.
Induction of Influenza A Virus-speck CTL.
￿
The methods were based on those de-
scribed previously (5). Briefly, peripheral blood lymphocytes (PBL) at 1 .5 X 106 cells/ml
were incubated in RPMI 1640 medium (Gibco Laboratories, Grand Island, NY), in the
absence of serum, with influenza virus at a final dilution of 1 :2,000 for 1 h at 37°C. FCS
(Gibco Laboratories) was added to 5%, and the flask was incubated for six more days.
Cells were harvested and resuspended in RPMI 1640, 10% FCS for use in lytic assays.
Nonsensitized cells were incubated without virus for 6 d.
Preparation of Target Cells.
￿
Autologous Epstein-Barr virus-transformed lymphoblas-
toid cells, which were shown previously to form the most sensitive target cells, were
resuspended to 106 in 100 Al RPMI 1640. Recombinant vaccinia virus, or wild type
vaccinia, 50-100 Al was added to give a multiplicity of infection of 10-50 pfu/cell,
together with 150 pCi Nab'Cr (Amersham Corp., Amersham, United Kingdom). After
incubation for 1 .5 h, cells were washed and resuspended in 1 ml RPMI 1640, 10% FCS.
They were incubated for 4 h at 37°C, washed three times in RPMI 1640 10% FCS, and
resuspended for the lytic assay. It has been shown (5) that cells infected with recombinant
vaccinia virus in this way have influenza virus antigen present, detectable by staining with
appropriate monoclonal antibody or by immunoprecipitation .
Lytic Assay.
￿
A standard procedure was used (2, 15), and killer/target ratios used are
shown in the figures. The percentage of specific "Cr released was calculated as [(release
by CTL) - (medium only release)] X 100/[(detergent only release) - (medium only
release)]. Each experimental point was measured in duplicate against quadruplicate410 VIRAL MOLECULES RECOGNIZED BY CYTOTOXIC T LYMPHOCYTES
controls in medium alone. Spontaneous "Cr release by recombinant vaccinia-infected
targets in medium alone varied between 15 and 25% of detergent-mediated lysis. Some
cells infected with wild-type vaccinia had spontaneous release of up to 30% ofdetergent
lysis.
Results
Recognition ofRecombinant Vaccinia Virus-infected Target Cells.
￿
CTL from six
donors whose lymphocytes gave an influenza A virus-specific HLA-restricted
response after stimulation in vitro were tested for recognition of recombinant
vaccinia virus-infected autologous Epstein-Barr virus-transformed lymphoblas-
toid cells. All of these CTL lysed autologous cells infected with some, but not
all, of the recombinant vaccinia viruses. In all cases, PBL that were cultured in
the absence of influenza virus (nonsensitized controls) gave only background
lysis of infected target cells (data not shown).
We found (Fig. 1) that target cells infected with PB2-VAC were clearly
recognized and lysed by CTL from four out of six donors; those infected with
NP-VAC by CTL from all donors; those infected with MI-VAC by all donors;
and those infected with M2-VAC were lysed weakly by one out of five donors.
Lysis of target cells infected with other recombinant vaccinia viruses, including
H2-VAC and NA-VAC, were close to the background levels of lysis seen with
uninfected cells.
HLA Restriction.
￿
The HLA types of the donors are shown in Table 1. IH,
CM, and JM have been shown by immunoprecipitation and isoelectric focusing
(IEF) ofmethionine-labeled cell lysates to have the commonest variant of HLA
A2, A2.1, whereas AM has the basic variant HLA A2 molecule, A2.2 (16). MG
and LG shared no HLA alleles with JM or IH, and yet CTL from all four of
these donors recognized autologous targets infected with NP-VAC and Ml-
VAC. This implies that no one allele determined specificity for any one viral
protein.
When influenza A virus-specific CTL were tested against HLA-A and -B
mismatched target cells that were infected with the recombinant vaccinia viruses,
they were not lysed (Fig. 2A and B). When tested on target cells that shared only
one or two HLA-A or -B antigens, it appeared that different HLA antigens
might influence which virus protein was recognized. Thus CM CTL lysed only
M1-VAC-infected JM cells when only HLA-A2 was shared, but showed a pref-
erence for NP when Al and B7 were shared. In the latter combination, M1-
VAC-infected cells were only lysed slightly more than the background levels seen
with NA-VAC (Fig. 2A). IH CTL also clearly recognized M1 through HLA-A2
(Fig. 2B).
Virus Specificity.
￿
We have generated polyclonal CTL from the same donor by
stimulating in vitro either with A virus X31, which is recombinant of ANT
60/68 and A/PR/8/34 with the 1968 surface glycoproteins (H3N2) but the 1934
internal proteins; or A/NT/60/68, with the 1968 surface glycoproteins (H3N2)
and the 1968 internal proteins. Such CTL showed identical patterns ofreactivity
with the recombinant vaccinia-infected target cells (Fig. 3). The recombinant
vaccinia viruses used to infect these target cells contained cDNA corresponding
to genes from A/PR/8/34 influenza virus. Thus recognition ofthe internal virus
proteins M1, NP, and PB2 was crossreactive with regard to virus subtype.%LYSIS 100,
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FIGURE 1 .
￿
Recognition of autologous target cells infected with recombinant vaccinia virus
by CTL from six donors. Lysis is shown on they axis, measured at an E/T cell ratio of 40:1
for each donor. The recombinant vaccinia viruses used are indicated above and below the
histogram. They were: PA, polymerase A; PB1, polymerase 131 ; PB2, polymerase 132; HA,
haemagglutinin; NP, nucleoprotein; NA, neuraminidase; MI, matrix 1 ; M2, matrix 2; NSl,
nonstructural protein 1; NS2, nonstructural protein; 0 uninfected cells.
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TABLE I
HLA Types ofDonors
Discussion
M1 NP NA
￿
M1 NP NA
￿
M1 NP NA
￿
M1 NP NA
CM
￿
JM(A2) AT(AlB71 AM(0)
5 15 45 5 15 45 5 15 45
IH
￿
VHfA2)
￿
MG (0)
FIGURE 2.
￿
(A) Recognition of recombinant vaccinia virus infected target cells by CM CTL.
Target cells were CM (autologous),JM (shared A2), AT (shared A1 and B7), andAM (shared
no HLA antigen), and were infected with M1-VAC (MI), NP-VAC (NP), or NA-VAC (NA).
The last was representative of background nonspecific lysis. (B) Recognition of recombinant
vaccinia virus infected target cells by IH CTL. E/T ratio on x axis, percent lysis, y axis. B
lymphoblastoid target cells were IH (autologous), VH (shares HLA-A2), and MG (HLA
missmatch), infected with M1 VAC, NP VAC or VAC.
Conventional influenza vaccine, when administered, results in a humoral
response with neutralizing antibodies directed towards surface viral glycopro-
teins, but poor stimulation of CTL memory (17). If an influenza vaccine that
Donor
A
HLA
B C DR
LG 1 29 44 37 6 ND
MG 1 30 13 37 6 7
CM 1 2 7 8 ND 2 3
JM 2 15 51 3 4
IH 2 3 7 15 3 7 2 4
AM 2* 32 49 60 3 7 4501 A/ X31
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FIGURE 3. Virus specificity of CM polyclonal CTL produced with A/X31 (H3N2, 1934
internal proteins) or A/NT/60/68 (H3N2, 1968 internal proteins). E/T ratio on x axis,
percent lysis on y axis. Target cells were autologous B lymphoblastoid cells infected with 10
pfu/cell vaccinia virus.
would stimulate crossreactive and crossprotective CTL is to be produced, it is
important to determine which viral proteins are recognized by human CTL and
whether HLA type influences this. It has been previously demonstrated, using
reassorted viruses to infect cells, that relatively rare virus subtype-specific murine
CTL clones recognized viral polymerase (12), haemagglutinin (15), or nucleo-
protein (18). Crossreactive mouse influenza-specific CTL were shown to recog-
nize nucleoprotein (10). Recognition of the matrix proteins by CTL has not been
described before.
Here we used a complete set of recombinant vaccinia viruses containing cDNA
that corresponded to each of the 10 influenza virus-encoded proteins. We were
able to demonstrate that influenza A virus-specific but subtype crossreactive
human CTL were able to recognize cells infected with NP-VAC (5), Ml-VAC,
and PB2-VAC. Target cells infected with H2-VAC and NA-VAC, where the
influenza virus product was demonstrable on the surface with antibody (data not
shown) were not recognized by A virus-polyclonal crossreactive CTL .
No subtype specificity has ever been seen in the human polyclonal CTL
response to influenza virus (2) . All donors used in this study were born before
1968 and may therefore be considered to have been exposed to H2 haemaglut-
tinin, which was present on the influenza viruses that circulated between 1957
and 1968. However, as CTL memory is relatively short lived (19), CTL specific
for H2 may no longer be present, explaining why H2 is not seen by crossreactive
CTL. Viruses of the H 1 subtype are currently prevalent, and one might therefore
expect target cells infected with H1-VAC to be detected by H1-specific subtype
CTL. However, when such target cells were tested with polyclonal CTL, HLA-
unrestricted lysis was observed (data not shown), possibly due to a lectin-like
effect. This phenomenon, which was not seen with H2-VAC or any of the other
recombinant vaccinia viruses, has meant that we have been unable to determine
whether subtype-specific CTL are present in these donors.
The lack of recognition of virus proteins other than NP, M1, and PB2 is not
attributable to lack of expression, since all 10 influenza gene products have been
detected by immunoprecipitation using specific antisera (G. Smith, unpublished414 VIRAL MOLECULES RECOGNIZED BY CYTOTOXIC T LYMPHOCYTES
data). Moreover, NP, HA, PA, PB1, PB2, and NSI targets have been recognized
by autologous murine CTL (Bennink, J. R., J. W. Yewdell, G. L. Smith, and B.
Moss; manuscript submitted for publication).
Recognition was HLA restricted. CTL from all the donors tested recognized
targets infected with NP-VAC and M1-VAC; PB2-VAC and M2-VAC (weakly)
were seen by some but not others. Two of the donors, MG and LG, shared no
HLA alleles with three ofthe other donors,JM, IH, and AM, and yet all saw NP
and MI . In MG and LG we know that nucleoprotein is seen in conjunction with
HLA-1337 (6). IH saw matrix protein in conjunction with HLA-A2 and CM CTL
appeared to see M1 with A2, and NP with A1 or B7. Such associations were not
exclusive, however. We know that LG and MG CTL see a particular epitope of
NP (amino acids 335-349) with B37 (7): obviously other epitopes exist and must
associate with different HLA antigens.
It may be that the HLA type of an individual determines which virus antigen
is seen predominantly, and indeed it is possible that some HLA antigens might
offer favorable responses to influenza, with survival advantages. Conversely,
there might be individuals totally unresponsive in terms of CTLs to influenza as
a result of their HLA type, but as such types would have been selected against
strongly they would be very rare. We have found that PBL from ^-70% ofdonors
in the United Kingdom fail to give a measurable influenza A virus-specific CTL
response (17). This nonresponder population includes individuals with both
HLA-A2 and -1337, and it seems likely that nonresponsiveness is normally a
consequence ofthe limited duration ofCTL memory (19).
CTL from each individual recognized at least two conserved viral antigens
(normally thought of as internal) accounting for influenza virus subtype cross-
reactivity, which is well documented. CTL prepared with both AX31 and
A/NT/60/68, which contain the 1934 and 1968 internal proteins, respectively,
reacted with M1, NP, and PB2 from the 1934 virus. The mechanism of recog-
nition of internal virus proteins in association with MHC antigens is not clear,
and nucleoprotein was not detectable on the surface of recombinant vaccinia-
infected B lymphoblastoid cells usinga monoclonal antibody 5/1 and a polyclonal
sheep antinucleoprotein serum (5). It has been shown that recognition ofautolo-
gous virus-infected target cells was not blocked by monoclonal antibodies specific
for viral proteins (20), implying that the viral proteins are not recognized by
CTL in their native form. The results are consistent with the view that CTL
recognition may involve processing of the viral antigen by the target cell and
that small peptide fragments of the antigen may be recognized in conjunction
with MHC class I on the cell surface (6, 21).
Summary
Human cytotoxic T cells specific for influenza A virus were tested for recog-
nition ofeach ofthe ten influenza A virus proteins expressed in target cells using
recombinant vaccinia viruses. They recognized the matrix M1, polymerase PB2,
and nucleoproteins of influenza virus in association with MHC class I antigens.
These internal viral proteins were seen by CTL in conjunction with one or more
of the available dependent HLA gene products. There was no detectable rec-
ognition ofinfluenza virus surface glycoproteins in target cells.We thank Dr. P. Palese (Mt. Sinai Medical School, New York) for cloned influenza genes
from A/PR/8/34, and Dr. R. Lamb (Northwestern University, Chicago, IL), for cDNAs
of M2 and NS2 from A/Udorn/72 .
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